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Nursing Implications 
Myasthenia Gravis and implications for the Certified Registered Nurse Anesthetist 
Matthew Predick BSN, CCRN 
Introduction 
In healthcare and, specifically 
anesthesia, there are many conditions 
that require various considerations by 
the prudent provider. An example of a 
condition requiring special attention is 
myasthenia gravis. Myasthenia gravis is 
an autoimmune disease in which 
skeletal muscle weakness and rapid 
fatigue result from destruction of 
nicotinic acetylcholine receptors [7]. 
Although the prevalence is not 
overwhelmingly high with most recent 
estimates of prevalence around 14 to 20 
per 100,000 people in the United States 
[5] and 20 per 100,000 worldwide [9], 
inappropriate perioperative 
management of those with this ailment 
can result in serious consequences. 
Understanding the pathophysiology, 
various treatments (both surgical and 
medical), and anesthetic implications 
can result in better outcomes for 
individuals with myasthenia gravis that 
require surgery. 
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Pathophysiology 
 Mr. Smith, a 52-year-old male, presents 
to his primary care physician whom he 
hasn’t seem in nearly ten years because 
not only does he need a physical before 
his carpal tunnel surgery planned for 
next month, but also because he has not 
been feeling well. Mr. Smith has been 
experiencing generalized muscle 
weakness that, at times, leaves him 
feeling short of breath. In addition to 
fatigue that does seem to resolve with 
rest, Mr. Smith has also been 
experiencing double vision, a 
“fluttering” sensation of his heart, 
difficulty swallowing, and drooping of 
his eyelid. After several blood tests were 
negative, including normal glucose and 
thyroid panel, and a thorough 
neurological examination was 
performed, Mr. Smith’s physician 
suspected myasthenia gravis so he 
ordered a tensilon test, which confirmed 
the diagnosis of myasthenia gravis. 
Mr. Smith presents with classic 
symptoms of myasthenia gravis and is 
within the typical age range for disease 
presentation in men, which is between 
50 and 60 years of age [8]. Weakness 
commonly affects the muscles of one or 
both eyes leading to ptosis and diplopia 
[4] and the age of onset in men is 
typically Visual disturbances affect more 
than half of patients with myasthenia 
gravis. Fatigue that resolves with rest 
and arrhythmias that result of 
inflammation of the myocardium are 
also symptoms common to the patient 
with myasthenia gravis [8]. Diagnosis of 
myasthenia gravis is not always 
straightforward and can be difficult at 
times. Various blood tests exist which 
include measurement of serum 
antibodies against acetylcholine 
receptors and muscle-specific receptor 
tyrosine kinase (MuSK) with the latter 
being present in nearly 40% of 
individuals with myasthenia gravis. 
Perhaps the most well known diagnostic 
for myasthenia gravis is the tensilon test 
in which tensilon, also known as 
edrophonium, is administered which 
inhibits the breakdown of acetylcholine. 
The increased amount of acetylcholine 
in an individual with myasthenia gravis 
will cause a momentary improvement of 
weakness. Other tests that can assist in 
the diagnosis of myasthenia gravis 
include electromyography, radiologic 
imaging of the chest and neck to assess 
for thymus alterations, and pulmonary 
function tests [10]. 
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Conclusion Significance of 
Pathophysiology 
To understand the pathophysiology of myasthenia gravis, one 
must first have an understanding of skeletal muscle 
depolarization and the receptors involved. When an electrical 
impulse reaches the presynaptic nerve terminal, an influx of 
calcium triggers the release of presynaptic acetylcholine. 
Approximately 150 to 200 vesicles that contain nearly 10,000 
molecules of acetylcholine each are released into the synaptic cleft 
and bind to nicotinic acetylcholine receptors. Nicotinic 
acetylcholine receptors are located on postsynaptic folds on motor 
end plates, which are located in close proximity to skeletal muscle. 
The binding of acetylcholine to the alpha sub-unit of the nicotinic 
acetylcholine receptor causes a conformational change in the 
receptor, opening a channel that allows for a rapid influx of 
sodium ions. The rapid influx of sodium ions depolarizes the 
motor end plate and skeletal muscle, which allows for muscular 
contraction [8].  The following picture depicts the neuromuscular 
junction and acetylcholine’s role in action potential propagation. 
[1] 
 
As mentioned earlier, myasthenia gravis is an autoimmune 
disorder in which antibodies target the nicotinic acetylcholine 
receptors and other proteins resulting in their destruction. 
Specifically, nearly 85% of people with myasthenia gravis have 
antibodies that target nicotinic acetylcholine receptors. Of the 
15% that do not have anti-acetylcholine antibodies, 70% have 
antibodies targeting other proteins involved in neuromuscular 
transmission that includes muscle specific tyrosine kinase. 
Regardless of the type of autoantibody muscle membrane 
destruction is caused by antibody activation of complement, 
disintegration of the postsynaptic membrane, and elimination 
of the postsynaptic folds (the primary location of nicotinic 
acetylcholine receptors). Investigation of thymus abnormalities 
(thymomas, atrophy, or hyperplasia) is warranted in patients 
with myasthenia gravis because the thymus major site for 
antibody production [2].  
 
 
- Most frequent symptom is 
muscle weakness. 
- Weakness occurs when 70%-
90% of nicotinic acetylcholine 
receptors are lost [6]. 
- Myasthenia gravis can classified, 
or staged, according to severity 
and muscles affected by the 
Osserman Staging system seen 
below. 
[3] 
Of significant importance is respiratory 
muscle weakness in patients with 
myasthenia gravis. Ineffective 
respiratory muscle function can cause a 
multitude of problems both 
perioperatively and in day-to-day life. 
The following schematic is a great 
representation of the pathologic effects 
that can result from respiratory muscle 
weakness.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[3] 
Decreased numbers of nicotinic acetylcholine 
receptors and the associated skeletal muscular 
weakness have important implications for the nurse 
anesthetist caring for the patient with myasthenia 
gravis perioperatively. A medication type frequently 
utilized by the nurse anesthetist to facilitate tracheal 
intubation and provide a motionless surgical field for 
the surgeon is neuromuscular blockers (NMBs). The 
two types of paralytics utilized today are depolarizing 
NMBs and non-depolarizing NMBs [11]. The only 
depolarizing NMB in use today is succinylcholine. 
Chemically, succinylcholine is composed of two 
molecules of acetylcholine (known as diacetylcholine) 
and causes muscular paralysis by joining to a nicotinic 
acetylcholine receptor causing a sustained muscular 
depolarization, preventing further action potentials 
from propagating. It differs from acetylcholine in that 
it is metabolized by pseudocholinesterase rather than 
acetylcholinesterase [8]. Due to the similarities 
between succinylcholine and acetylcholine, it is not 
surprising that patients with myasthenia gravis are 
often resistant to this medication, necessitating 
increased dosages to achieve acceptable paralysis 
(usually 2.5 times more).  
Patients with myasthenia gravis, however, are 
considerably more sensitive to non-depolarizing 
NMBs, which achieve paralysis by binding to nicotinic 
acetylcholine receptors and preventing depolarization 
[8]. For example, in patients with myasthenia gravis, 
the potency of atracurium and vecuronium, two non-
depolarizing NMBs, potency is increased two times. 
Because of the increased potency, caution must be 
used with non-depolarizers. If a non-depolarizing 
agent is needed, the initial dose should be reduced by 
50-67% and closely monitored with a peripheral 
nerve stimulator. Intravenous induction agents like 
propofol or etomidate and/or volatile anesthetics like 
desflurane can be used to facilitate endotracheal 
intubation, however, the degree of respiratory 
depression can be magnified so caution needs to be 
exercised with these agents as well. Similar to 
induction agents, opioids can cause exacerbate 
respiratory muscle weakness and too need to be used 
with caution. Because of the profound respiratory 
weakness than can result postoperatively, ventilator 
support is frequently needed in patients with 
myasthenia gravis [11]. Some experts recommend 
discontinuation of cholinesterase inhibitors, 
medications used to treat myasthenia gravis, 
preoperatively in those with mild disease as these 
agents can complicate anesthetic management. 
Reversal of non-depolarizing neuromuscular blockers 
in these patients can result in a cholinergic crisis. It 
should be noted that discontinuation of cholinesterase 
inhibitors remains controversial. Finally, adequate 
return of muscular strength must be ensured prior to 
extubation so respiratory distress/ failure dose not 
occur [8].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Myasthenia gravis is a disease 
process that can cause profound 
weakness both perioperatively 
and in every day life. 
Understanding the 
pathophysiology of the disease, 
as is seen in the case of Mr. 
Smith, can provide the nurse 
anesthetist with a sound basis 
so as to optimally manage the 
anesthetic.   
